Trials show a new drug Kadcyla may be the biggest advance since Herceptin. Kadcyla combines antibody-drug Herceptin with traditional chemotherapy, killing cancer cells while reducing the side effects.

In trials done in the UK women lived six months longer than those on a standard drug combination used to fight the more aggressive HER2-positive breast cancer.